GeoVax to Showcase Innovative Vaccines and Therapies at BIO International Convention 2025

GeoVax Labs, Inc., a clinical-stage biotechnology company, is set to participate in the 2025 BIO International Convention, the premier global event for the biotechnology industry. This participation marks a significant opportunity for GeoVax to engage with key stakeholders, including potential partners and investors, to discuss its innovative pipeline of vaccines and immunotherapies. The company's focus on developing solutions for infectious diseases and cancer, including its GEO-MVA vaccine for Mpox and smallpox, GEO-CM04S1 for COVID-19, and Gedeptin® for solid tumors, highlights its commitment to addressing critical health challenges.

The BIO International Convention serves as a critical platform for companies like GeoVax to showcase their advancements and forge strategic partnerships. GeoVax's presence at the convention underscores the importance of its work in pandemic preparedness, oncology, and biodefense, areas of significant public health interest. The company's efforts to expand its manufacturing capabilities and align with public and private sector priorities further demonstrate its potential impact on global health outcomes.

GeoVax's participation in the convention is a testament to the company's innovative approach to vaccine and therapy development. With its lead clinical programs in COVID-19 and oncology, GeoVax is at the forefront of addressing some of the most pressing health challenges of our time. The company's strong intellectual property portfolio and worldwide rights to its technologies and products position it as a key player in the biotechnology industry, with the potential to make significant contributions to public health and biodefense.